Another first-generation NAMPT inhibitor, GMX1777, also displayed an improved therapeutic index against cancer cells with low NAPRT expression in vivo, when administered at high doses with nicotinic acid rescue [32]. The gene discussed is NAPRT; the disease is cancer.